{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:11:54Z","timestamp":1790125914916,"version":"4.0.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Primary gastric squamous cell carcinoma (GSCC) is rare, typically associated with poor survival rates and unsatisfactory outcomes from conventional treatments including surgery, radiotherapy, and chemotherapy. It remains unclear whether nivolumab is as effective for GSCC as it is for gastric adenocarcinoma. Herein, we present the case of a 66-year-old man diagnosed with Epstein-Barr virus-positive metastatic GSCC, involving the liver, multiple lymph nodes, and invasion into the spleen, pancreatic body and tail, and splenic vein. The patient received nivolumab with oxaliplatin, leucovorin, and fluorouracil plus local radiotherapy as first-line treatment; nivolumab, paclitaxel polymer micelles, and carboplatin as the second-line treatment, and nivolumab and apatinib as the third-line treatment. The patient responded remarkably (survival period for 49 months) with manageable treatment toxicity. Genomic and immune characteristics were analyzed to understand the underlying disease mechanisms. In conclusion, integrated therapy (immunotherapy, chemotherapy, local radiotherapy, and anti-angiogenic therapy) may be the ideal treatment approach for patients with GSCC with multiple metastases; however, prospective studies are needed to verify its efficacy.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1552052","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T05:29:38Z","timestamp":1754544578000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Long-term response control in a patient with metastatic gastric squamous cell carcinoma treated with nivolumab and chemoradiotherapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Yu-ying","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-bin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-hui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-tong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-jun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-xia","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004720","article-title":"The clinicopathological features and prognostic factors of gastric squamous cell carcinoma","volume":"95","author":"Dong","year":"2016","journal-title":"Medicine"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2022.0715","article-title":"Oncologic outcomes of patients with resectable primary gastric squamous cell carcinoma: a systematic review","volume":"35","author":"Schizasa","year":"2022","journal-title":"Ann Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.21037\/jgo.2018.10.06","article-title":"Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis","volume":"10","author":"Akce","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5230\/jgc.2014.14.1.58","article-title":"A rare case of primary squamous cell carcinoma of the stomach and a review of the 56 cases reported in Japan","volume":"14","author":"Wakabayashi","year":"2014","journal-title":"J Gastric Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0040","article-title":"In vitro characterization of the anti-PD-1 antibody nivolumab,BMS-936558, and in vivo toxicology in non-human primates","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.3390\/cancers13246158","article-title":"Disruption of her2-induced PD-L1 inhibits tumor cell immune evasion in patient-derived gastric cancer organoids","volume":"13","author":"Chakrabarti","year":"2021","journal-title":"Cancers"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.12.006","article-title":"A PD1 targeted nano-delivery system based on epigenetic alterations of T cell responses in the treatment of gastric cancer","volume":"24","author":"Hu","year":"2022","journal-title":"Mol Ther - Oncolytics"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI74894","article-title":"Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis","volume":"125","author":"Reissfelder","year":"2014","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1078155220915774","article-title":"Long-term response control in a patient with metastatic squamous cell lung cancer after treatment with nivolumab: a case report","author":"Pamp\u0131n-Sanchez","year":"2020","journal-title":"J Oncol Pharm Practice"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.05.001","article-title":"Meta-analysis shows that prevalence of epstein\u2013barr virus-positive gastric cancer differs based on sex and anatomic location","volume":"137","author":"Murphy","year":"2009","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.759652","article-title":"Case report: favorable response and manageable toxicity to the combination of camrelizumab, oxaliplatin, and oral S-1 in a patientWith advanced epstein\u2013barr virs-associated gastric cancer","volume":"11","author":"Lv","year":"2022","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/s40792-021-01301-9","article-title":"A case of Epstein Barr virus-associated primary squamous cell carcinoma of stomach","volume":"7","author":"Katsura","year":"2021","journal-title":"Surg Case Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000316","article-title":"Positive status of epstein-barr virus as a biomarker for gastric cancer immunotherapy: A prospective observational study","volume":"43","author":"Xie","year":"2020","journal-title":"J Immunother"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-022-01329-2","article-title":"Pattern of lymph node metastases in gastric cancer: a side-study of the multicenter LOGICA-trial","volume":"25","author":"Jongh","year":"2022","journal-title":"Gastric Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/01.MP.0000076980.73826.C0","article-title":"Lymphocyte-rich gastric cancer: associations with epstein-barr virus, microsatellite instability, histology, and survival","volume":"16","author":"Grogg","year":"2003","journal-title":"Modern Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.586752","article-title":"Clinicopathological and immunomicroenvironment characteristics of epstein\u2013barr virus-associated gastric cancer in a chinese population","volume":"10","author":"Jia","year":"2021","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5230\/jgc.2016.16.1.1","article-title":"Epstein-barr virus-associated gastric carcinoma and specific features of the accompanying immune response","volume":"16","author":"Cho","year":"2016","journal-title":"J Gastric Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9076","article-title":"Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers","volume":"7","author":"Derks","year":"2016","journal-title":"Oncotarget"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/ng.982","article-title":"Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer","volume":"43","author":"Wang","year":"2011","journal-title":"Nat Genet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000438","article-title":"ARID1A alterations function as a biomarker for longer progression- free survival after anti- PD-1\/PD- L1 immunotherapy","volume":"8","author":"Okamura","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003580","article-title":"Randomized, open- label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival","volume":"9","author":"Shah","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4461","article-title":"Prognostic factors to predict the survival in patients with advanced gastric cancer who receive later-line nivolumab monotherapy\u2014The Asahikawa Gastric Cancer Cohort Study (AGCC)","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.3390\/cancers13143433","article-title":"The anti-VEGF(R) drug discovery legacy: improving attrition rates by breaking the vicious cycle of angiogenesis in cancer","volume":"13","author":"Ribatti","year":"2021","journal-title":"Cancers"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01769","article-title":"Squamous cell carcinomas of the head and neck cancer response to programmed cell death protein-1 targeting and differential expression of immunological markers: A case report","volume":"9","author":"Merhi","year":"2018","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13955","article-title":"Complete pathological response after neoadjuvant short-course immunotherapy with ipilimumab and nivolumab in locally advanced MSI-H\/dMMR rectal cancer","volume":"26","author":"Trojan","year":"2021","journal-title":"Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12957-022-02624-z","article-title":"Locally advanced rectal cancer receiving total neoadjuvant therapy combined with nivolumab: a case report and literature review","volume":"20","author":"Mori","year":"2022","journal-title":"World J Surg Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1552052\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T05:29:40Z","timestamp":1754544580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1552052\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2025.1552052"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1552052","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"article-number":"1552052"}}